AveXis (AveXis) Inventory Turnover : 0.00 (As of Mar. 2018)

View and export this data going back to 2016. Start your Free Trial

What is AveXis Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. AveXis's Cost of Goods Sold for the three months ended in Mar. 2018 was $0.00 Mil. AveXis's Average Total Inventories for the quarter that ended in Mar. 2018 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AveXis Inventory Turnover Historical Data

The historical data trend for AveXis's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AveXis Inventory Turnover Chart

AveXis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Inventory Turnover

AveXis Quarterly Data
	Dec13	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Inventory Turnover	Get a 7-Day Free Trial										-	-	-	-	-

AveXis Inventory Turnover Calculation

AveXis's Inventory Turnover for the fiscal year that ended in Dec. 2017 is calculated as

	Inventory Turnover (A: Dec. 2017 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2017 )	/ (	(Total Inventories (A: Dec. 2016 )	+	Total Inventories (A: Dec. 2017 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

AveXis's Inventory Turnover for the quarter that ended in Mar. 2018 is calculated as

	Inventory Turnover (Q: Mar. 2018 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2018 )	/ (	(Total Inventories (Q: Dec. 2017 )	+	Total Inventories (Q: Mar. 2018 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

AveXis (NAS:AVXS) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AveXis's Days Inventory for the three months ended in Mar. 2018 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2018 )	/	Cost of Goods Sold (Q: Mar. 2018 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AveXis's Inventory to Revenue for the quarter that ended in Mar. 2018 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2018 )	/	Revenue (Q: Mar. 2018 )
	=	0	/	0
	=

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

AveXis Inventory Turnover Related Terms

Thank you for viewing the detailed overview of AveXis's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

AveXis (AveXis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AveXis Inc (NAS:AVXS) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.avexis.com

AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.

Executives

Sean P. Nolan	director, officer: President & CEO	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Session R.a. Ii	officer: Sr. VP, Corp Strategy	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Paul B Manning	director, other: Former 10% Owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Sukumar Nagendran	officer: Sr. VP & Chief Medical Officer	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Frank Verwiel	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
James J Litalien	officer: SrVP/Chief Reg&Quality Officer	C/O SOMAXON PHARMACEUTICALS, INC., 3721 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO CA 92130
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Rick Modi	officer: Chief Business Officer	C/O AVEXIS INC, 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Phillip B. Donenberg	officer: Chief Financial Officer	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Joao Md Siffert	director	20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056
Bong Y Koh	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Deerfield International Master Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	director, 10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017